GENTIAN VIOLET: WHAT WE KNOW AND WHAT IS AHEAD OF US

被引:3
作者
Dragan, Jedrzej [1 ]
Michalak, Sylwia Sulimiera [1 ]
机构
[1] Univ Zielona, Fac Med & Hlth Sci, Gora, Poland
来源
ACTA POLONIAE PHARMACEUTICA | 2019年 / 76卷 / 03期
关键词
p53; crystal violet; gentian violet; fungal infection; bacterial infection; STAPHYLOCOCCUS-AUREUS; OROPHARYNGEAL; CANDIDIASIS; METABOLISM; INFECTION; NYSTATIN; THERAPY;
D O I
10.32383/appdr/102482
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
At present, the only active substance of Gentian Violet (GV) is methylrosaniline - a triphenylmethane dye of which amino group contains 2 methyl groups. GV can be used to treat uncomplicated bacterial and/or yeast infections, support antibiotic therapy of more severe infections, but also to protect medical equipment against colonization by microorganisms. In the light of recent studies, there are many new possibilities for GV application. It has been shown to be effective in the treatment of viral infections, some chronic skin diseases and oncology. GV can induce apoptosis of tumor cells among others by elevating caspase 8, inhibiting NADPH oxidases, decreasing mitochondrial thioredoxin 2 or inhibiting STAT3/SOX2 axis. Preclinical and in vitro studies have also demonstrated GV efficacy in the treatment of breast cancer, melanoma tumors and cutaneous T-cell lymphoma. There is no unambiguous evidence indicating the toxicity of GV, whereas its safety has been proven by its long history of use, its inclusion in numerous guidelines and its legal trade and distribution with no specific approval requested in many countries around the world. The article gathers the available knowledge about GV and its potential use in the future.
引用
收藏
页码:389 / 396
页数:8
相关论文
共 50 条
  • [31] Virome in immunodeficiency: what we know currently
    Wang, Hu
    Xu, Siqi
    Li, Shuang
    Su, Bin
    Sherrill-Mix, Scott
    Liang, Guanxiang
    CHINESE MEDICAL JOURNAL, 2023, 136 (22) : 2647 - 2657
  • [32] Brain temperature: What do we know?
    Rango, Mario
    Arighi, Andrea
    Bresolin, Nereo
    NEUROREPORT, 2012, 23 (08) : 483 - 487
  • [33] MicroRNAs in inflammatory bowel disease: What do we know and what can we expect?
    De Oliveira, Ellen Cristina Souza
    Quaglio, Ana Elisa Valencise
    Grillo, Thais Gagno
    Di Stasi, Luiz Claudio
    Sassaki, Ligia Yukie
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (16) : 2184 - 2190
  • [34] Pathogen Flow: What We Need to Know
    Nunn, Charles L.
    Hare, Brian
    AMERICAN JOURNAL OF PRIMATOLOGY, 2012, 74 (12) : 1084 - 1087
  • [35] Schistosomiasis and Infertility: What Do We Know?
    Ribeiro, Ana Rita
    Luis, Carla
    Fernandes, Ruben
    Botelho, Monica C.
    TRENDS IN PARASITOLOGY, 2019, 35 (12) : 964 - 971
  • [36] Zika virus: what we need to know?
    Javed, Farakh
    Manzoor, Khanzadi N.
    Ali, Mubashar
    Haq, Irshad U.
    Khan, Abid A.
    Zaib, Assad
    Manzoor, Sobia
    JOURNAL OF BASIC MICROBIOLOGY, 2018, 58 (01) : 3 - 16
  • [37] Adjuvants approved for human use: What do we know and what do we need to know for designing good adjuvants?
    Reyes, Cesar
    Patarroyo, Manuel A.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 945
  • [38] A scoping review of penile implant biofilms-what do we know and what remains unknown?
    Leong, Joon Yau
    Capella, Courtney E.
    D'Amico, Maria J.
    Isguven, Selin
    Purtill, Caroline
    Machado, Priscilla
    Delaney, Lauren J.
    Henry, Gerard D.
    Hickok, Noreen J.
    Forsberg, Flemming
    Chung, Paul H.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2022, 11 (08) : 1210 - 1221
  • [39] Malignant carotid body tumors: What we know, what we do, and what we need to achieve. A systematic review of the literature
    Piazza, Cesare
    Lancini, Davide
    Tomasoni, Michele
    Zafereo, Mark
    Vander Poorten, Vincent
    Hanna, Ehab
    Makitie, Antti A.
    Fernandez-Alvarez, Veronica
    Kowalski, Luiz P.
    Chiesa-Estomba, Carlos
    Ferlito, Alfio
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (03): : 672 - 687
  • [40] SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't
    Lingor, Paul
    Demleitner, Antonia F.
    Wolff, Andreas W.
    Feneberg, Emily
    JOURNAL OF NEURAL TRANSMISSION, 2022, 129 (09) : 1155 - 1167